{"id":133,"date":"2024-07-15T10:00:00","date_gmt":"2024-07-15T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=133"},"modified":"2025-09-02T01:19:22","modified_gmt":"2025-09-02T01:19:22","slug":"china-bd-2024-ascentage-and-takeda-enters-an-option-license-on-bcr-abl-tki-olverembatinib","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2024\/133.html","title":{"rendered":"[China BD 2024] Ascentage and Takeda enters an Option License on BCR-ABL TKI\u00a0Olverembatinib"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><\/h2>\n\n\n\n<p>Announced Date: 2024-06-14 (June 14, 2024)<\/p>\n\n\n\n<p>Asset Name: Olverembatinib<\/p>\n\n\n\n<p>Licensor: Ascentage Pharma (China)\u00a0<\/p>\n\n\n\n<p>Licensee (Buyer): Takeda (Japan)<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality:  Small Molecule, Oral<\/p>\n\n\n\n<p>Asset Target: third-generation BCR-ABL tyrosine kinase inhibitor (TKI)<\/p>\n\n\n\n<p>Potential Indication: Chronic myeloid leukemia (CML) and other hematological cancers<\/p>\n\n\n\n<p>Current Stage: Olverembatinib is currently approved and marketed in China.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>The option would allow Takeda to license global rights to develop and commercialize olverembatinib in all territories outside of mainland China, Hong Kong, Macau, Taiwan and Russia.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment of\u00a0$100 million,<\/p>\n\n\n\n<p>Milestone payments.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p>Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)<\/p>\n\n\n\n<p><a href=\"https:\/\/www.takeda.com\/newsroom\/newsreleases\/2024\/takeda-signs-option-agreement-with-ascentage-pharma-to-enter-into-exclusive-global-license-for-olverembatinib\/\">Takeda Signs Option Agreement with Ascentage Pharma for Olverembatinib<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2024-06-14 (June 14, 2024) Asset Name: Olverembatinib Licensor: Ascentage Pharma (China)\u00a0 Licensee (Buyer): Takeda &hellip; <a title=\"[China BD 2024] Ascentage and Takeda enters an Option License on BCR-ABL TKI\u00a0Olverembatinib\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2024\/133.html\"><span class=\"screen-reader-text\">[China BD 2024] Ascentage and Takeda enters an Option License on BCR-ABL TKI\u00a0Olverembatinib<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-133","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=133"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/133\/revisions"}],"predecessor-version":[{"id":134,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/133\/revisions\/134"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=133"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=133"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}